Phase II Trial of Piperazinedione in the Treatment of Advanced or Recurrent Endometrial Carcinoma A Gynecologic Oncology Group Study
- 1 February 1986
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 9 (1) , 21-23
- https://doi.org/10.1097/00000421-198602000-00006
Abstract
Twenty-three patients with advanced or recurrent endometrial carcinoma no longer amenable to control with surgery and/or radiotherapy were entered into study. Twenty-two actually received therapy with piperazinedione at a dose of 9 mg/m2 intravenously every 3 weeks. One partial responder was observed. Adverse effects were primarily manifested as myelosuppression, and were significant but tolerable. Due to the low order of activity observed, this drug is not recommended for further study in the treatment of endometrial carcinoma.This publication has 1 reference indexed in Scilit:
- Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary A Gynecologic Oncology Group studyAmerican Journal of Clinical Oncology, 1984